# CART123 + Ruxolitinib in Relapsed/Refractory AML

> **NCT06768476** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 12 (estimated)

## Conditions studied

- Relapsed AML
- Refractory AML

## Interventions

- **BIOLOGICAL:** CART123 Cells
- **DRUG:** Ruxolitinib 10 MG
- **DRUG:** Ruxolitinib 5 MG

## Key facts

- **NCT ID:** NCT06768476
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2045-03
- **Final completion:** 2045-03
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06768476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06768476, "CART123 + Ruxolitinib in Relapsed/Refractory AML". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06768476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*